Genelux
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
$2.66
After-hours close−0.01 (−0.31%)
At close$2.67(−7.29%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.20 | −$0.21 | −6.8% |
| May 2026 | −$0.18 | −$0.20 | −11.1% |
| Mar 2026 | −$0.22 | −$0.24 | −9.1% |
| Nov 2025 | −$0.23 | −$0.21 | +8.7% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Jan 2023 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.20 | — | — | — | — | — |
| Aug 13, 2026 | −$0.20 | −$0.21 | −6.8% | — | — | — |
| May 7, 2026 | −$0.18 | −$0.20 | −11.1% | — | — | — |
| Mar 19, 2026 | −$0.22 | −$0.24 | −9.1% | $8.0K | $8.0K | 0.0% |
| Nov 5, 2025 | −$0.23 | −$0.21 | +8.7% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 6, 2025 | ||||||
| Mar 28, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 29, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 15, 2023 | ||||||
| Jan 26, 2023 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||